<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03600363</url>
  </required_header>
  <id_info>
    <org_study_id>RJ-NHL-1805</org_study_id>
    <nct_id>NCT03600363</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients</brief_title>
  <official_title>A Prospective Randomized Controlled Phase II Clinical Trial of Metformin in the Maintenance Therapy of High Risk Diffuse Large B Lymphoma / Stage III Follicular Lymphoma Patients With Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to evaluate the therapeutic effect of metformin as a maintenance therapy in high
      risk patients with complete remission of diffuse large B lymphoma / stage III follicular
      lymphoma after chemotherapy in the initial R-CHOP (cyclophosphamide, doxorubicin,
      vincristine, and prednisone, plus the monoclonal antibody rituximab) regimen
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of randomization until the date of trail closed or date of death from any cause, whichever came first, up to 100 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress Free Survival</measure>
    <time_frame>From date of randomization until the date of trail closed or disease progressed, whichever came first, up to 100 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Stage III Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>metformin arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>metformin (1.0g, bid) as a maintenance therapy in patients with complete remission</description>
    <arm_group_label>metformin arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>oral placebos as a maintenance therapy</description>
    <arm_group_label>control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient age &gt;14 years old;

          2. Pathological types include: diffuse large B lymphoma, and stage III follicular
             lymphoma;

          3. At the initial stage of therapy, received standard R-CHOP regimen and complete
             remission after the first course of treatment;

          4. After complete remission, not consider to receive hematopoietic stem cell
             transplantation or chimeric antigen receptor T cell immunotherapy;

          5. Serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase
             (SGPT) not exceed 2 times of the normal upper limit;

          6. Serum total bilirubin and creatinine not exceed 1.5 times of the normal upper limit;

          7. Serum creatinine not exceed 1.5mg/dl;

          8. Patients with high risk factors, including age &gt; 60 year, or with diabetes/ impaired
             glucose tolerance, or with International Prognostic Index (IPI) score â‰¥2.

          9. Sign informed consent file.

        Exclusion Criteria:

          1. Past medical history of high doses of cytarabine, methotrexate and rituximab
             maintenance therapy;

          2. Past medical history of any type of hematopoietic stem cell transplantation;

          3. Past medical history of lactic acidosis;

          4. Extreme weight loss failure, malnutrition or dehydration patients;

          5. Pregnant women or lactating women, or women who do not take contraceptive measures for
             childbearing age;

          6. Alopecia, mental retardation or psychiatric disorders that affect the patient's normal
             informed consent;

          7. Type 1.2 diabetes with ketoacidosis, liver function or renal insufficiency, pulmonary
             insufficiency, heart failure, acute myocardial infarction, severe infection and
             trauma, major surgery and clinical hypotension or hypoxia;

          8. Diabetes complicated with severe chronic complications (such as diabetic nephropathy,
             diabetic retinopathy);

          9. Any other serious complications occurred, depending on the outcome of the study;

         10. Before the intravenous pyelography or anterior angiography;

         11. Alcoholics;

         12. Deficiency of Vitamin B12, folic acid or iron.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weili Zhao Zhao</last_name>
    <phone>64370045</phone>
    <phone_ext>610707</phone_ext>
    <email>zhao.weili@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xing Fan</last_name>
    <phone>64370045</phone>
    <phone_ext>610707</phone_ext>
    <email>fx-86@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huijuan Zhong</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Weili</investigator_full_name>
    <investigator_title>Deputy Director of Hematology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

